Sanofi Genzyme Overview
- Founded
- 1981

- Status
- Private
- Employees
- 10,000

- Latest Deal Type
- M&A
- Latest Deal Amount
- $20.4B

- Investors
- 1
Sanofi Genzyme General Information
Description
Manufacturer of human health-care products. The company focuses on rare genetic disease disorders, renal diseases, orthopedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. It operates as a biotechnology company worldwide.
Contact Information
- 50 Binney Street
- Cambridge, MA 02142
- United States
Sanofi Genzyme Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 08-Apr-2011 | $20.4B | 000.00 | 000.00 | Completed | Generating Revenue |
1. IPO | 05-Jun-1986 | 000.00 | 000.00 | Completed | Generating Revenue |
Sanofi Genzyme Comparisons
Industry
000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialSanofi Genzyme Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 0&0 |
Sanofi Genzyme Patents
Sanofi Genzyme Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210380719-A1 | Rabbit antibodies to human immunoglobulins g | Pending | 01-Jun-2020 | 00000000000 | |
US-20210332115-A1 | Humanized anti-complement factor bb antibodies and uses thereof | Pending | 20-Apr-2020 | 000000000 | |
US-20210292391-A1 | Modified binding polypeptides for optimized drug conjugation | Pending | 28-Feb-2020 | 000000000 | |
US-20210244803-A1 | Compositions and methods for treating pompe disease | Pending | 08-Feb-2020 | 000000000 | |
US-20210251982-A1 | Methods for treating neurological symptoms associated with lysosomal storage diseases | Pending | 03-Feb-2020 | A61K31/4748 |
Sanofi Genzyme Executive Team (35)
Sanofi Genzyme Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSanofi Genzyme Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Perseus (Bethesda) | PE/Buyout | 000 0000 | 000000 0 |
Sanofi Genzyme Investments & Acquisitions (40)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 | 30-Apr-2015 | 00000 0000 | 0000 | Drug Discovery | |
00000000 | 07-Jan-2015 | 0000 00000 | 00.000 | Electronic Equipment and Instruments | |
000000 000000 | 12-Jan-2012 | 00000 0000 | 000.00 | Consulting Services (B2B) | |
0000 00000 00 | 10-Jan-2012 | 00000 0000 | 00000 | Drug Discovery | |
Zealand Pharma | 23-Dec-2009 | Later Stage VC | 00000 | Pharmaceuticals |
Sanofi Genzyme Subsidiaries (6)
Company Name | Industry | Location | Founded |
---|---|---|---|
ZyStor Therapeutics | Biotechnology | Wauwatosa, WI | 2004 |
000000000 | Drug Discovery | Amsterdam, Netherlands | 0000 |
00000000000 | Pharmaceuticals | New York, NY | 0000 |
000000 00000000 | Biotechnology | Bridgewater, NJ | 0000 |
00000 | Surgical Devices | Lexington, MA | 0000 |
Sanofi Genzyme Exits (13)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000000 | 30-Apr-2015 | 00000 00000 00 | 0000 | Completed |
|
000000 000000000 | 12-Jan-2012 | 00000 00000 00 | 000.00 | Completed |
|
0000 00000 000 | 10-Jan-2012 | 00000 00000 00 | 00000 | Completed |
|
0000000 000000 | 23-Dec-2009 | 00000 00000 00 | 00000 | Completed |
|
Great Wall Semiconductor | 08-Jul-2009 | Later Stage VC | Completed |
|